{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:28:11Z","timestamp":1791163691138,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4725,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.exphem.2009.04.001","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T23:34:19Z","timestamp":1241739259000},"page":"831-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line"],"prefix":"10.1016","volume":"37","author":[{"given":"Shuqing","family":"L\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2009.04.001_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.exphem.2009.04.001_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.001_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/156800905774574075","article-title":"Anti-angiogenic and anti-tumor properties of proteasome inhibitors","volume":"5","author":"Daniel","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2009.04.001_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000468683","article-title":"Molecular structure of 20S and 26S proteasomes","volume":"47","author":"Tanahashi","year":"1993","journal-title":"Enzyme Prot"},{"key":"10.1016\/j.exphem.2009.04.001_bib5","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2009.04.001_bib6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2009.04.001_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethazone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2009.04.001_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12185-008-0218-9","article-title":"Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience","volume":"89","author":"L\u00fc","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2009.04.001_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.001_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2009.04.001_bib11","first-page":"10","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"15","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2009.04.001_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.leu.2403400","article-title":"Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro","volume":"18","author":"Satou","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.001_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208212","article-title":"Efficacy and mechanism of action of the proteasome HTLV-I associated adult T-cell leukemia\/lymphoma","volume":"24","author":"Nasr","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2009.04.001_bib14","article-title":"The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562\/A02","author":"L\u00fc","year":"2009","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.exphem.2009.04.001_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-200708010-00001","article-title":"Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors","volume":"8","author":"Cheriyath","year":"2007","journal-title":"Drugs R D"},{"key":"10.1016\/j.exphem.2009.04.001_bib16","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2004-02-0547","article-title":"Targeting mitochondria to overcome conventional and bortezomib\/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells","volume":"104","author":"Chauhan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.001_bib17","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2009.04.001_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.2006.06132.x","article-title":"Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib","volume":"134","author":"Shringarpure","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.001_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line","volume":"326","author":"L\u00fc","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2009.04.001_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the PSMB5 Gene Contributes to Bortezomib Resistance in T Lymphoblastic lymphoma\/Leukemia Cells Derived from Jurkat Line","volume":"36","author":"L\u00fc","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2009.04.001_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.001_bib22","first-page":"296","volume":"151","author":"Small","year":"2008","journal-title":"Stability of reference genes for real-time PCR analyses in channel catfish (Ictalurus punctatus) tissues under varying physiological conditions. Comp Biochem Physiol B Biochem Mol Biol"},{"key":"10.1016\/j.exphem.2009.04.001_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.exphem.2009.04.001_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:14Z","timestamp":1759566434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X09001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0301472X09001283"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2009.04.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2009.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}